Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Rotrosen

Showing results (11-20 of 157) with videos related to

Pageof 16
Sort By:
Addiction Science & Clinical Practice|March 7, 2021
Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)"Matisyahu Shulman, Roger Weiss, John Rotrosen, et al.
Drug and Alcohol Dependence Reports|October 3, 2022
Under-representation of key demographic groups in opioid use disorder trialsKara E Rudolph, Matthew Russell, Sean X Luo, et al.
Drug and Alcohol Dependence|September 17, 2021
Optimizing opioid use disorder treatment with naltrexone or buprenorphineKara E Rudolph, Iván Díaz, Sean X Luo, et al.
Lancet (London, England)|December 10, 2013
Care for patients with grave alcohol use disorders - Authors' replyRyan P McCormack, Arthur R Williams, John Rotrosen, et al.
Substance Abuse|August 2, 2019
Health-related material needs and substance use among emergency department patientsEvan Gerber, Lillian Gelberg, John Rotrosen, et al.
Plos One|November 6, 2019
A 3' UTR SNP rs885863, a cis-eQTL for the circadian gene VIPR2 and lincRNA 689, is associated with opioid addictionOrna Levran, Matthew Randesi, John Rotrosen, et al.
Addiction Science & Clinical Practice|January 29, 2014
Outcomes among buprenorphine-naloxone primary care patients after Hurricane SandyBabak Tofighi, Ellie Grossman, Arthur R Williams, et al.
Addiction (Abingdon, England)|August 2, 2021
Association between dynamic dose increases of buprenorphine for treatment of opioid use disorder and risk of relapseKara E Rudolph, Matisyahu Shulman, Marc Fishman, et al.
Journal of Addictive Diseases|April 15, 2011
Barriers to providing health services for HIV/AIDS, hepatitis C virus infection and sexually transmitted infections in substance abuse treatment programs in the United StatesEdmund J Bini, Steven Kritz, Lawrence S Brown, et al.
Drug and Alcohol Dependence|February 1, 2025
Effects of randomization to buprenorphine or naltrexone for OUD on cannabis use outcomes: A secondary analysis of the X:BOT trialMatisyahu Shulman, Tse-Hwei Choo, Kaitlyn Ohrtman, et al.
Pageof 16

Showing results (11-20 of 157) with videos related to

Sort By:
Pageof 16
Addiction Science & Clinical Practice|March 7, 2021
Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)"Matisyahu Shulman, Roger Weiss, John Rotrosen, et al.
Drug and Alcohol Dependence Reports|October 3, 2022
Under-representation of key demographic groups in opioid use disorder trialsKara E Rudolph, Matthew Russell, Sean X Luo, et al.
Drug and Alcohol Dependence|September 17, 2021
Optimizing opioid use disorder treatment with naltrexone or buprenorphineKara E Rudolph, Iván Díaz, Sean X Luo, et al.
Lancet (London, England)|December 10, 2013
Care for patients with grave alcohol use disorders - Authors' replyRyan P McCormack, Arthur R Williams, John Rotrosen, et al.
Substance Abuse|August 2, 2019
Health-related material needs and substance use among emergency department patientsEvan Gerber, Lillian Gelberg, John Rotrosen, et al.
Plos One|November 6, 2019
A 3' UTR SNP rs885863, a cis-eQTL for the circadian gene VIPR2 and lincRNA 689, is associated with opioid addictionOrna Levran, Matthew Randesi, John Rotrosen, et al.
Addiction Science & Clinical Practice|January 29, 2014
Outcomes among buprenorphine-naloxone primary care patients after Hurricane SandyBabak Tofighi, Ellie Grossman, Arthur R Williams, et al.
Addiction (Abingdon, England)|August 2, 2021
Association between dynamic dose increases of buprenorphine for treatment of opioid use disorder and risk of relapseKara E Rudolph, Matisyahu Shulman, Marc Fishman, et al.
Journal of Addictive Diseases|April 15, 2011
Barriers to providing health services for HIV/AIDS, hepatitis C virus infection and sexually transmitted infections in substance abuse treatment programs in the United StatesEdmund J Bini, Steven Kritz, Lawrence S Brown, et al.
Drug and Alcohol Dependence|February 1, 2025
Effects of randomization to buprenorphine or naltrexone for OUD on cannabis use outcomes: A secondary analysis of the X:BOT trialMatisyahu Shulman, Tse-Hwei Choo, Kaitlyn Ohrtman, et al.
Pageof 16